Precision Subtyping and Prognostic Study of Heart Failure Based on Multi-Omics Integration and Clinical Indicators: A Prospective Single-Center Cohort Study

NCT07355088 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2026-01-21

No results posted yet for this study

Summary

This is a prospective single-center cohort study conducted at The First Affiliated Hospital of Xinjiang Medical University, aiming to enroll 400 patients with chronic heart failure (including HFrEF, HFmrEF, HFpEF) and 200 healthy controls.We will collect clinical data (e.g., NYHA class, NT-proBNP), multi-omics samples (genome, proteome, metabolome, gut microbiome), and imaging indicators (e.g., EAT density, myocardial strain) from participants at baseline. For patients treated with SGLT2 inhibitors, we will also track dynamic changes in multi-omics during follow-up.The main purpose is to build a composite risk prediction model (integrating multi-omics and clinical indicators) to predict the 1-year composite endpoint (heart failure rehospitalization or all-cause death). Secondary goals include identifying specific molecular profiles related to heart failure phenotypes, exploring the "gut-heart axis" mechanism, and finding early biomarkers for SGLT2 inhibitor response.All participants will be followed up for at least 12 months, and the study will strictly comply with ethical norms and protect the privacy of participants.

Conditions

  • Chronic Heart Failure
  • Heart Failure With Reduced Ejection Fraction (HFrEF)
  • Heart Failure With Preserved Ejection Fraction (HFPEF)
  • Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)

Sponsors & Collaborators

  • Xinjiang Medical University

    lead OTHER

Principal Investigators

  • ailiman mahemut, MD · First Affiliated Hospital of Xinjiang Medical University

  • xiang xie, MD · First Affiliated Hospital of Xinjiang Medical University

  • refukait abuduhalike, MD · First Affiliated Hospital of Xinjiang Medical University

  • aihaidan abuduwayiti, MD · First Affiliated Hospital of Xinjiang Medical University

  • li zhao, MD · First Affiliated Hospital of Xinjiang Medical University

  • yujun guo, MM · First Affiliated Hospital of Xinjiang Medical University

  • zhiying wen, MM · First Affiliated Hospital of Xinjiang Medical University

  • yanxiao li, MM · Xinjiang Medical University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2027-01-01
Completion
2028-03-01

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07355088 on ClinicalTrials.gov